GLMD
Galmed Pharmaceuticals Ltd. NASDAQ Listed Mar 13, 2014$0.63
Pre-mkt
$0.66
+6.42%
Mkt Cap $3.4M
52w Low $0.41
11.2% of range
52w High $2.34
50d MA $0.62
200d MA $1.03
P/E (TTM)
-0.2x
EV/EBITDA
0.1x
P/B
0.2x
Debt/Equity
0.0x
ROE
-65.3%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$0.62
200d MA
$1.03
Avg Volume
3.1M
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
16 Tiomkin Street · Ramat Gan, L3 6578317 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.38 | -0.92 | -142.1% | 0.49 | +7.1% | +8.2% | +10.2% | +6.3% | +16.3% | +27.0% | — |
| Nov 26, 2025 | AMC | -0.54 | -0.33 | +38.9% | 0.92 | -3.0% | +1.7% | +5.5% | +3.8% | +15.8% | +22.3% | — |
| Aug 28, 2025 | AMC | -0.83 | 0.63 | +175.9% | 1.38 | -2.9% | -8.0% | -8.0% | -6.5% | -7.2% | -1.4% | — |
| May 22, 2025 | AMC | -0.89 | -0.62 | +30.3% | 1.41 | -1.4% | -1.4% | +5.0% | -3.5% | +1.4% | +1.4% | — |
| Apr 2, 2025 | AMC | — | -11.76 | — | 1.50 | +0.0% | -2.7% | -10.7% | -17.3% | -13.3% | -5.3% | — |
| Nov 14, 2024 | AMC | — | -2.31 | — | 3.10 | -2.3% | -5.5% | -5.2% | -3.2% | -4.5% | -9.7% | — |
| Aug 28, 2024 | AMC | — | 2.16 | — | 3.22 | +0.0% | -1.9% | +5.0% | -2.8% | -12.7% | +6.2% | — |
| May 30, 2024 | AMC | — | -2.76 | — | 4.37 | +4.8% | +1.6% | -1.6% | +1.6% | -6.2% | -3.7% | — |
| Apr 4, 2024 | AMC | -0.32 | -11.76 | -3575.0% | 3.96 | -2.5% | +2.8% | +19.9% | +17.7% | +21.2% | +27.0% | — |
| Nov 22, 2023 | AMC | -0.27 | -2.88 | -966.7% | 3.53 | +8.8% | +7.6% | +4.8% | +24.1% | +19.0% | +20.7% | — |
| Aug 9, 2023 | AMC | -0.34 | -11.40 | -3252.9% | 10.92 | -2.2% | -7.1% | -7.5% | -6.6% | -11.0% | -15.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 4 | Maxim Group | Downgrade | Buy → Hold | — | $1.46 | $1.40 | -4.1% | -8.2% | -15.1% | -11.0% | -2.7% | -13.7% |
| Jul 24 | Maxim Group | Upgrade | Hold → Buy | — | $13.80 | $14.88 | +7.8% | +5.2% | +3.5% | +7.0% | +0.9% | +3.5% |
| Aug 8 | Maxim Group | Downgrade | Buy → Hold | — | $79.29 | $82.58 | +4.1% | +2.2% | -2.7% | -4.8% | -0.3% | -6.9% |
| Aug 8 | Canaccord Genuity | Downgrade | Buy → Hold | — | $79.29 | $82.58 | +4.1% | +2.2% | -2.7% | -4.8% | -0.3% | -6.9% |
| May 18 | Raymond James | Downgrade | Outperform → Market Perform | — | $105.09 | $105.10 | +0.0% | -7.7% | -14.4% | -4.3% | +11.3% | +1.0% |
| May 3 | Raymond James | Maintains | Outperform → Outperform | — | $219.49 | $194.30 | -11.5% | -25.1% | -27.5% | -30.3% | -37.7% | -43.4% |
| May 3 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $219.49 | $194.30 | -11.5% | -25.1% | -27.5% | -30.3% | -37.7% | -43.4% |
| May 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $425.49 | $424.59 | -0.2% | +5.3% | +9.5% | +9.5% | +9.9% | +11.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $615.29 | $638.68 | +3.8% | +14.6% | +13.5% | +6.4% | +3.2% | +2.6% |
| Jan 8 | Raymond James | Maintains | Outperform → Outperform | — | $609.89 | $609.89 | +0.0% | +0.9% | +0.3% | -0.3% | -0.6% | +2.7% |
| Nov 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $687.26 | $687.26 | +0.0% | -1.3% | +9.2% | +0.8% | +0.5% | +1.8% |
| May 22 | B. Riley Securities | Downgrade | Buy → Neutral | — | $1054.27 | $976.91 | -7.3% | -0.9% | -8.9% | -12.8% | -18.1% | -18.9% |
| May 22 | B. Riley FBR | Downgrade | Buy → Neutral | — | $1054.27 | $976.91 | -7.3% | -0.9% | -8.9% | -12.8% | -18.1% | -18.9% |
| May 15 | Raymond James | Maintains | Outperform → Outperform | — | $913.94 | $953.52 | +4.3% | +0.2% | -3.3% | +17.3% | +19.7% | +15.4% |
| Mar 13 | Stifel | Maintains | Buy → Buy | — | $609.89 | $647.68 | +6.2% | +3.5% | +3.8% | +3.2% | -2.7% | +0.6% |
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $609.89 | $647.68 | +6.2% | +3.5% | +3.8% | +3.2% | -2.7% | +0.6% |
| Mar 13 | B. Riley FBR | Maintains | Buy → Buy | — | $609.89 | $647.68 | +6.2% | +3.5% | +3.8% | +3.2% | -2.7% | +0.6% |
| Feb 4 | Craig-Hallum | Maintains | Buy → Buy | — | $926.54 | $1056.07 | +14.0% | +13.0% | +11.5% | +12.8% | +4.5% | +13.8% |
| Jul 22 | Laidlaw & Co. | Maintains | Buy → Buy | — | $1122.64 | $1212.59 | +8.0% | -9.5% | -7.2% | -0.3% | -3.5% | -2.3% |
| Dec 12 | B. Riley FBR | Maintains | Buy → Buy | — | $1424.89 | $1478.86 | +3.8% | +18.6% | +9.3% | +4.9% | +3.4% | -1.3% |
| Jul 20 | Raymond James | Maintains | Outperform → Outperform | — | $2702.25 | $2786.81 | +3.1% | -0.1% | +1.7% | -3.9% | -4.0% | -5.2% |
| Jul 13 | Stifel Nicolaus | Maintains | Buy → Buy | — | $2297.45 | $2569.11 | +11.8% | +19.3% | +17.5% | +15.0% | +9.7% | +17.6% |
| Jul 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1979.01 | $1980.81 | +0.1% | -4.1% | +16.1% | +38.5% | +36.5% | +33.5% |
| Jun 13 | Maxim Group | Maintains | Buy → Buy | — | $3164.62 | $3186.21 | +0.7% | +2.1% | -8.7% | -6.8% | -15.2% | -10.8% |
| Mar 15 | Maxim Group | Upgrade | Hold → Buy | — | $1113.64 | $1243.18 | +11.6% | +6.9% | +7.1% | +6.1% | +1.6% | -1.0% |
| Feb 14 | Maxim Group | Downgrade | Buy → Hold | — | $1701.95 | $649.48 | -61.8% | -42.4% | -26.4% | -37.4% | -43.7% | -40.6% |
| Nov 15 | Roth Capital | Maintains | Buy → Buy | — | $1327.74 | $1390.70 | +4.7% | -2.3% | +3.7% | +5.8% | +10.2% | +8.4% |
| Oct 6 | Seaport Global | Maintains | Buy → Buy | — | $1655.17 | $1655.17 | +0.0% | +1.3% | -3.3% | -3.3% | -1.6% | -1.1% |
| Jun 23 | H.C. Wainwright | Maintains | Buy → Buy | — | $1955.62 | $2036.58 | +4.1% | +2.8% | +3.0% | +0.8% | -3.9% | -9.8% |
| May 6 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $1543.63 | $1603.00 | +3.8% | +2.6% | +5.2% | +2.0% | -0.7% | -0.2% |
| Apr 15 | Roth Capital | Maintains | Buy → Buy | — | $1579.61 | $1651.57 | +4.6% | +19.6% | +27.3% | +25.2% | +13.6% | +15.3% |
| May 9 | MLV & Co. | Maintains | Buy → Buy | — | $1235.44 | $1253.97 | +1.5% | +2.1% | +3.8% | +3.7% | +2.5% | -2.3% |
No insider trades available.
No recent filings available.
Data updated apr 25, 2026 11:37am
· Source: massive.com